Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : KalVista Pharmaceuticals
Deal Size : $22.0 million
Deal Type : Licensing Agreement
KalVista Licenses Sebetralstat to Kaken for HAE Market in Japan
Details : Under the licensing agreement, Kaken will holds the rights of KVD900 (sebetralstat) in Japan. It is being evaluated for the treatment of hereditary angioedema.
Product Name : KVD900
Product Type : Other Small Molecule
Upfront Cash : $11.0 million
April 08, 2025
Lead Product(s) : Sebetralstat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : KalVista Pharmaceuticals
Deal Size : $22.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Sirolimus Protein-bound Particle
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Whitehawk Therapeutics
Deal Size : $100.0 million
Deal Type : Divestment
Whitehawk Finalizes Aadi Sale To Kaken In Strategic Transformation
Details : Through the divestment, Kaken assumes ownership of FYARRO (sirolimus protein-bound particles for injectable suspension) used to treat adults with malignant perivascular epithelioid cell tumor.
Product Name : Fyarro
Product Type : Antibiotic
Upfront Cash : $100.0 million
March 26, 2025
Lead Product(s) : Sirolimus Protein-bound Particle
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Whitehawk Therapeutics
Deal Size : $100.0 million
Deal Type : Divestment
Lead Product(s) : KP-723
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Johnson & Johnson
Deal Size : $1,247.5 million
Deal Type : Licensing Agreement
Kaken, J&J Ink Potential $1.2B-Plus STAT6 Deal
Details : Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723, a preclinical STAT6 inhibitor, for autoimmune and allergic diseases, including atopic dermatitis.
Product Name : KP-723
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
December 26, 2024
Lead Product(s) : KP-723
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Johnson & Johnson
Deal Size : $1,247.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Fresh Tracks Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sofpironium bromide gel was deemed to be safe and well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan. Japan is the first country to approve sofpironium bromide with commercial launch expected la...
Product Name : Ecclock
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Fresh Tracks Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
